Nektar Therapeutics began a quiet period on September 8, 2026, lasting until it publicly announces data from the 24-week off-treatment follow-up of its Phase 2b REZOLVE-AA study. The defined endpoint matters to investors because the data announcement will mark the end of the restricted communications period.

Key Highlights

  • Nektar said the quiet period follows the approach used during prior Phase 2b REZOLVE study data disclosures.
  • The communications restriction will remain in place until the follow-up data is publicly announced.
  • Nektar is preparing to publicly announce follow-up results from the REZOLVE-AA study.
  • REZOLVE-AA is a Phase 2b investigation of rezpegaldesleukin in severe-to-very-severe alopecia areata.

REZOLVE-AA Follow-Up Data Sets the Endpoint

The quiet period applies while Nektar (NASDAQ: NKTR) prepares for the public announcement of results from the follow-up period. The study is a Phase 2b investigation of rezpegaldesleukin for severe-to-very-severe alopecia areata. The company has not stated a separate end date. Instead, the quiet period will continue until the follow-up data is publicly announced.

Public Data Announcement Will End Quiet Period

That announcement will end the quiet period, according to Nektar’s disclosure. The update therefore links the communications restriction directly to the planned REZOLVE-AA data release.